The estimated Net Worth of Allan R Tessler is at least $4.62 millier dollars as of 9 March 2020. Allan Tessler owns over 400 units of BioCardia stock worth over $4,624 and over the last 18 years Allan sold BCDA stock worth over $0.
Allan has made over 11 trades of the BioCardia stock since 2006, according to the Form 4 filled with the SEC. Most recently Allan bought 400 units of BCDA stock worth $199,200 on 9 March 2020.
The largest trade Allan's ever made was buying 20,000 units of BioCardia stock on 21 September 2017 worth over $740,000. On average, Allan trades about 666 units every 51 days since 2006. As of 9 March 2020 Allan still owns at least 1,700 units of BioCardia stock.
You can see the complete history of Allan Tessler stock trades at the bottom of the page.
Allan's mailing address filed with the SEC is 200 S. 108TH AVE., , OMAHA, NE, 68154.
Over the last 8 years, insiders at BioCardia have traded over $2,555,815 worth of BioCardia stock and bought 6,474,371 units worth $6,325,055 . The most active insiders traders include Phillip Md Et Al Frost Gamm..., Simon H Stertzer et Richard M Krasno. On average, BioCardia executives and independent directors trade stock every 48 days with the average trade being worth of $1,321,186. The most recent stock trade was executed by Phillip Md Et Al Frost Gamm... on 19 January 2024, trading 129,802 units of BCDA stock currently worth $55,815.
we are a clinical-stage regenerative medicine company developing novel therapeutics for cardiovascular diseases with large unmet medical needs. biocardia is developing proprietary comprehensive biotherapeutic solutions for cardiovascular disease in its cardiamp™ and cardiallo™ therapies. clinical results supporting both therapeutic programs are compelling and build upon the most rigorous data in the field to date with intramyocardial delivery of marrow-derived cells. these programs are enabled by the company's helix™ transendocardial delivery systems and morph® vascular access products, which are partnered to enable other promising biotherapeutic programs.
BioCardia executives and other stock owners filed with the SEC include: